Edgeworth Client Prevails in Rare Antitrust Trial
In July 2022, Endo Pharmaceuticals won a jury trial, defeating claims that it had entered into an anticompetitive agreement with Impax Laboratories to delay a generic version of Endo’s Opana ER pharmaceutical. After eight years of litigation, the jury found that the settlement between Endo and Impax was not anticompetitive under the antitrust rule of reason.
Edgeworth CEO, Dr. John Johnson, provided expert testimony on the issues of antitrust injury and damages on behalf of Endo during the class certification phase of the matter.
- Chief Executive Officer